Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage
Advanced Science · 2024
DOI: 10.1002/advs.202308248 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Manman Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Department of Chemistry, University of Science…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Ferritins, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key R&D Program of China, Plans for Major Provincial Science & Technology Projects, National Natural Science Foundation of China.
Abstract (Originalsprache)
Increasing immunotherapy response rate and durability can lead to significant improvements in cancer care. To address this challenge, a novel multivalent immune checkpoint therapeutic platform is constructed through site‐specific ligation of anti‐PD‐L1 nanobody (Nb) on ferritin (Ftn) nanocage. Nb‐Ftn blocks PD‐1/PD‐L1 interaction and downregulates PD‐L1 levels via endocytosis‐induced degradation. In addition, the cage structure of Ftn allows encapsulation of indocyanine green (ICG), an FDA‐approved dye. Photothermal treatment with Nb‐Ftn@ICG induces immunogenic death of tumor cells, which improves systemic immune response via maturation of dendritic cells and enhanced infiltration of T cells. Moreover, Nb‐Ftn encapsulation significantly enhances cellular uptake, tumor accumulation and retention of ICG. In vivo assays showed that this nanoplatform ablates the primary tumor, suppresses abscopal tumors and inhibits tumor metastasis, leading to a prolonged survival rate. This work presents a novel strategy for improving cancer immunotherapy using multivalent nanobody‐ferritin conjugates as immunological targeting and enhancing carriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, Department of Chemistry, University of Science and Technology of China, Hefei, 230001, China.
- The CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Basic Medical Sciences, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University o…
- Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, 75230, USA.
ORCID-Profile: Yangzhong Liu
Förderung
- National Key R&D Program of China
- Plans for Major Provincial Science & Technology Projects
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Liu, M., Jin, D., Yu, W., Yu, J., Cao, K., Cheng, J., Zheng, X., Wang, A., & Liu, Y. (2024). Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage. Advanced Science. https://doi.org/10.1002/advs.202308248
Vancouver
Liu M, Jin D, Yu W, Yu J, Cao K, Cheng J, et al. Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage. Advanced Science. 2024. doi:10.1002/advs.202308248
BibTeX
@article{Liu2024,
author = {Liu, Manman and Jin, Duo and Yu, Wenxin and Yu, Jiaji and Cao, Kaiming and Cheng, Junjie and Zheng, Xiaohu and Wang, Andrew and Liu, Yangzhong},
title = {Enhancing Tumor Immunotherapy by Multivalent Anti‐PD‐L1 Nanobody Assembled via Ferritin Nanocage},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202308248}
}
EUVIMED